Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 9:5:55.
doi: 10.3389/fphar.2014.00055. eCollection 2014.

The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting

Affiliations
Review

The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting

María A Antor et al. Front Pharmacol. .

Abstract

Postoperative nausea and vomiting (PONV) is one of the most common and undesirable complaints recorded in as many as 70-80% of high-risk surgical patients. The current prophylactic therapy recommendations for PONV management stated in the Society of Ambulatory Anesthesia (SAMBA) guidelines should start with monotherapy and patients at moderate to high risk, a combination of antiemetic medication should be considered. Consequently, if rescue medication is required, the antiemetic drug chosen should be from a different therapeutic class and administration mode than the drug used for prophylaxis. The guidelines restrict the use of dexamethasone, transdermal scopolamine, aprepitant, and palonosetron as rescue medication 6 h after surgery. In an effort to find a safer and reliable therapy for PONV, new drugs with antiemetic properties and minimal side effects are needed, and scopolamine may be considered an effective alternative. Scopolamine is a belladonna alkaloid, α-(hydroxymethyl) benzene acetic acid 9-methyl-3-oxa-9-azatricyclo non-7-yl ester, acting as a non-selective muscarinic antagonist and producing both peripheral antimuscarinic and central sedative, antiemetic, and amnestic effects. The empirical formula is C17H21NO4 and its structural formula is a tertiary amine L-(2)-scopolamine (tropic acid ester with scopine; MW = 303.4). Scopolamine became the first drug commercially available as a transdermal therapeutic system used for extended continuous drug delivery during 72 h. Clinical trials with transdermal scopolamine have consistently demonstrated its safety and efficacy in PONV. Thus, scopolamine is a promising candidate for the management of PONV in adults as a first line monotherapy or in combination with other drugs. In addition, transdermal scopolamine might be helpful in preventing postoperative discharge nausea and vomiting owing to its long-lasting clinical effects.

Keywords: antiemetic; nausea; pharmacodynamics; pharmacokinetics; postoperative; prophylaxis; transdermal scopolamine; vomiting.

PubMed Disclaimer

References

    1. Apfel C. C., Laara E., Koivuranta M., Greim C. A., Roewer N. (1999). A simplified risk scores for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 91 693–700 10.1097/00000542-199909000-00022 - DOI - PubMed
    1. Apfel C. C., Zhang K., George E., Shi S., Jalota L., Hornuss C., et al. (2010). Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clin. Ther. 32 1987–2002 10.1016/j.clinthera.2010.11.014 - DOI - PubMed
    1. Ayromlooi J., Tobias M., Berg P. (1980). The effects of scopolamine and ancillary analgesics upon the fetal heart rate recording. J. Reprod. Med. 25 323–326 - PubMed
    1. Bailey P. L., Streisand J. B., Pace N. L., Bubbers S. J., East K. A., Mulder S., et al. (1990). Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy. Anesthesiology 72 977–980 10.1097/00000542-199006000-00005 - DOI - PubMed
    1. Briggs G. G., Freeman R. K., Yaffe S. J. (1994). Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk 4th Edn Williams and Wilkins: Baltimore

LinkOut - more resources